U.S., Sept. 25 -- ClinicalTrials.gov registry received information related to the study (NCT07189871) titled '177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors' on Sept. 11.
Brief Summary: A Phase 1/2a Dose Escalation and Expansion Study of the Safety, Tolerability, and Preliminary Clinical Activity of 177LuBetaBart, a 177Lu-Labeled Anti-B7-H3 Monoclonal Antibody, in Patients with Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors
Study Start Date: Nov., 2025
Study Type: INTERVENTIONAL
Condition:
Castration-Resistant Prostate Cancer (CRPC)
Colorectal Cancer
NSCLC (Non-small Cell Lung Cancer)
Ovarian Cancer
Cervical Cancer
Endometrial Cancer
TNBC, Tripl...